Amneal expects to meet or exceed 2024 full-year guidance; net leverage ~4x

Amneal Pharmaceuticals, Inc.

2024-FY EPS reported -$0.38 revenue$2,793,957,000

Expects to meet net revenue ($2.70-2.80B), adjusted EBITDA ($610-630M), and adjusted diluted EPS ($0.57-0.63).
Expects to exceed operating cash flow guidance ($280-320M) and capital expenditure guidance ($60-70M).
Estimates net leverage at approximately 4x as of December 31, 2024.
Guidance includes 100% of AvKARE EBITDA; adjusted EPS accounts for 35% non-controlling interest.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.